Emerging Infectious Disease ISSN: 1080-6059

Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies

Pedro Piccardo

, Larisa Cervenakova, Irina Vasilyeva, Oksana Yakovleva, Igor Bacik, Juraj Cervenak, Carroll McKenzie, Lubica Kurillova, Luisa Gregori, Kitty Pomeroy, and David M. Asher

Author affiliations: University of Edinburgh, Easter Bush, UK, (P. Piccardo); Food and Drug Administration, Kensington, Maryland, USA (P. Piccardo, I. Bacik, J. Cervenak, L. Kurillova, L. Gregori, K. Pomeroy, D.M. Asher); Holland Laboratory American Red Cross, Rockville, Maryland, USA (L. Cervenakova, I. Vasilyeva, O. Yakovleva, C. McKenzie)

Main Article

Figure 4

Western blot of brain extract from C57/Bl mouse inoculated with 22L mouse-adapted scrapie agent (lanes 1, 2); NIH-3T3 cells exposed to normal mouse brain and passaged 30 times (lane 3); NIH-3T3 (lane 4) and L929 (lane 5) cells exposed to 22L scrapie agent and passaged 30 times. Nonproteinase K [PK]–treated samples (lane 1), PK-treated samples (lanes 2–5). Western blots were probed with prion protein monoclonal antibody 6H4.

Figure 4. Western blot of brain extract from C57/Bl mouse inoculated with 22L mouse-adapted scrapie agent (lanes 1, 2); NIH-3T3 cells exposed to normal mouse brain and passaged 30 times (lane 3); NIH-3T3 (lane 4) and L929 (lane 5) cells exposed to 22L scrapie agent and passaged 30 times. Nonproteinase K [PK]–treated samples (lane 1), PK-treated samples (lanes 2–5). Western blots were probed with prion protein monoclonal antibody 6H4.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.